In patients with LM from melanoma harboring BRAF V600E mutations, there are reports of LM response to BRAF inhibitors such as dabrafenib and vemurafenib72 and the MEK inhibitor trametinib.73 Combined BRAF and MEK inhibitor therapy in BRAF-driven LM malignancies may be effective in patients naïve to these agents. The gene discussed is MAP2K7; the disease is melanoma.